Available Technology

Novel Rift Valley Fever Virus Vaccines

This invention relates to recombinant Rift Valley fever (RVF) viruses containing deletions in one or more virulence genes. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent RVF infection in livestock and humans. The recombinant RVF viruses grow to high titers, provide protective immunity following a single injection, and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus. Additionally, this technology relates to a method of using reverse genetics to generate recombinant RVF viruses.
Patent Abstract: 
This invention relates to recombinant Rift Valley fever (RVF) viruses containing deletions in one or more virulence genes. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent RVF infection in livestock and humans. The recombinant RVF viruses grow to high titers, provide protective immunity following a single injection, and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus. Additionally, this technology relates to a method of using reverse genetics to generate recombinant RVF viruses.
Benefits 
In vivo evidence shows single-dose protection -Allows for discrimination between vaccinated and naturally-infected subjects -Useful for controlled screening of therapeutic compounds
applications 
Inventors: 

Cesar Albarino

Brian Bird (CDC)

Brian Bird(CDC)➽ more inventions...

Cesar Albarino

Patent Number: 
PCT/US2008/087023 US Application No. 12/809,561 US
Internal Laboratory Ref #: 
E-254-2013/2
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin